Titanium platelet-rich fibrin (T-PRF) as high-capacity doxycycline delivery system
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
OBJECTIVES: Titanium platelet-rich fibrin (T-PRF), a second-generation autogenous blood concentrate with tough and thick fibrin meshwork activated by a titanium tube, was used as a drug carrier for doxycycline (Doxy) by injection. The objective of this study is to evaluate the loading capacity of T-PRF, release kinetics of doxycycline-loaded T-PRF, and its antibacterial effects against S. aureus and P. aeruginosa.
MATERIALS AND METHODS: The T-PRF and collagen were loaded with Doxy as T-PRF/Doxy and Collagen/Doxy, and their release and antibacterial activities against S. aureus and P. aeruginosa were investigated. Chemical characterization and morphological analysis were performed.
RESULTS: In comparison with collagen, approximately sevenfold more Doxy, 281 mg/g, was loaded into T-PRF. It was found that 25% of the loaded Doxy was released from T-PRF compared to only 12% from collagen within 72 h. The largest inhibition zone diameter (IZD) was observed for T-PRF/Dox with 32 ± 6 mm and 37 ± 5 mm for P. aereginosa and S. aureus, respectively. However, only 10 ± 5 mm and 10 ± 6 mm IZD were observed for bare T-PRF, and no inhibition zone was observed for the Collagen/Doxy group. A dense fibrin structure was visualized on SEM images of the T-PRF/Doxy group compared to the T-PRF group.
CONCLUSIONS: T-PRF has higher Doxy loading capacity and long-acting antibacterial effects compared to collagen. T-PRF was shown to have potential autogenous long-term drug-carrying capability for doxycycline. Also, the potential fibrinophilic properties of Doxy were observed to strengthen the structure of T-PRF.
CLINICAL RELEVANCE: T-PRF is an autogenous drug career with high loading capacity and extended antibacterial effects for doxycycline. Doxycycline molecules can be visible on T-PRF fibers. This study suggests that T-PRF/Dox could be used as a proper antibiotic delivery device in the treatments of periodontitis and peri-implantitis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Clinical oral investigations - 26(2022), 8 vom: 02. Aug., Seite 5429-5438 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ercan, Esra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9001-31-4 |
|---|
| Anmerkungen: |
Date Completed 18.08.2022 Date Revised 23.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00784-022-04510-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340302569 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340302569 | ||
| 003 | DE-627 | ||
| 005 | 20231226004833.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00784-022-04510-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340302569 | ||
| 035 | |a (NLM)35501503 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ercan, Esra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Titanium platelet-rich fibrin (T-PRF) as high-capacity doxycycline delivery system |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.08.2022 | ||
| 500 | |a Date Revised 23.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a OBJECTIVES: Titanium platelet-rich fibrin (T-PRF), a second-generation autogenous blood concentrate with tough and thick fibrin meshwork activated by a titanium tube, was used as a drug carrier for doxycycline (Doxy) by injection. The objective of this study is to evaluate the loading capacity of T-PRF, release kinetics of doxycycline-loaded T-PRF, and its antibacterial effects against S. aureus and P. aeruginosa | ||
| 520 | |a MATERIALS AND METHODS: The T-PRF and collagen were loaded with Doxy as T-PRF/Doxy and Collagen/Doxy, and their release and antibacterial activities against S. aureus and P. aeruginosa were investigated. Chemical characterization and morphological analysis were performed | ||
| 520 | |a RESULTS: In comparison with collagen, approximately sevenfold more Doxy, 281 mg/g, was loaded into T-PRF. It was found that 25% of the loaded Doxy was released from T-PRF compared to only 12% from collagen within 72 h. The largest inhibition zone diameter (IZD) was observed for T-PRF/Dox with 32 ± 6 mm and 37 ± 5 mm for P. aereginosa and S. aureus, respectively. However, only 10 ± 5 mm and 10 ± 6 mm IZD were observed for bare T-PRF, and no inhibition zone was observed for the Collagen/Doxy group. A dense fibrin structure was visualized on SEM images of the T-PRF/Doxy group compared to the T-PRF group | ||
| 520 | |a CONCLUSIONS: T-PRF has higher Doxy loading capacity and long-acting antibacterial effects compared to collagen. T-PRF was shown to have potential autogenous long-term drug-carrying capability for doxycycline. Also, the potential fibrinophilic properties of Doxy were observed to strengthen the structure of T-PRF | ||
| 520 | |a CLINICAL RELEVANCE: T-PRF is an autogenous drug career with high loading capacity and extended antibacterial effects for doxycycline. Doxycycline molecules can be visible on T-PRF fibers. This study suggests that T-PRF/Dox could be used as a proper antibiotic delivery device in the treatments of periodontitis and peri-implantitis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Doxycycline | |
| 650 | 4 | |a Drug delivery | |
| 650 | 4 | |a P. aeruginosa | |
| 650 | 4 | |a S. aureus | |
| 650 | 4 | |a T-PRF | |
| 650 | 4 | |a Titanium platelet–rich fibrin | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Fibrin |2 NLM | |
| 650 | 7 | |a 9001-31-4 |2 NLM | |
| 650 | 7 | |a Titanium |2 NLM | |
| 650 | 7 | |a D1JT611TNE |2 NLM | |
| 650 | 7 | |a Doxycycline |2 NLM | |
| 650 | 7 | |a N12000U13O |2 NLM | |
| 700 | 1 | |a Suner, Selin S |e verfasserin |4 aut | |
| 700 | 1 | |a Silan, Coskun |e verfasserin |4 aut | |
| 700 | 1 | |a Yilmaz, Selehattin |e verfasserin |4 aut | |
| 700 | 1 | |a Siddikoglu, Duygu |e verfasserin |4 aut | |
| 700 | 1 | |a Sahiner, Nurettin |e verfasserin |4 aut | |
| 700 | 1 | |a Tunali, Mustafa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical oral investigations |d 1998 |g 26(2022), 8 vom: 02. Aug., Seite 5429-5438 |w (DE-627)NLM094938687 |x 1436-3771 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2022 |g number:8 |g day:02 |g month:08 |g pages:5429-5438 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00784-022-04510-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2022 |e 8 |b 02 |c 08 |h 5429-5438 | ||